Show simple item record

dc.contributor.authorLibraty, Daniel H.
dc.contributor.authorEndy, Timothy P.
dc.contributor.authorHoung, Huo-Shu H.
dc.contributor.authorGreen, Sharone
dc.contributor.authorKalayanarooj, Siripen
dc.contributor.authorSuntayakorn, Saroj
dc.contributor.authorChansiriwongs, Wanya
dc.contributor.authorVaughn, David W.
dc.contributor.authorNisalak, Ananda
dc.contributor.authorEnnis, Francis A.
dc.contributor.authorRothman, Alan L.
dc.date2022-08-11T08:09:09.000
dc.date.accessioned2022-08-23T16:19:31Z
dc.date.available2022-08-23T16:19:31Z
dc.date.issued2002-05-01
dc.date.submitted2017-08-30
dc.identifier.citationJ Infect Dis. 2002 May 1;185(9):1213-21. Epub 2002 Apr 16. doi:10.1086/340365 <a href="https://doi.org/10.1086/340365">Link to article on publisher's site</a>
dc.identifier.issn0022-1899 (Linking)
dc.identifier.doi10.1086/340365
dc.identifier.pmid12001037
dc.identifier.urihttp://hdl.handle.net/20.500.14038/35069
dc.description.abstractDengue hemorrhagic fever (DHF), the most severe form of illness following infection with a dengue virus, is characterized by plasma leakage, thrombocytopenia, and hepatic inflammation. The interrelationships among virus burden, immune activation, and development of DHF were examined in 54 children with secondary dengue-3 virus infections participating in a prospective, hospital-based study. DHF was associated with higher mean plasma viremia early in illness and earlier peak plasma interferon-gamma levels. Maximum plasma viremia levels correlated with the degree of plasma leakage and thrombocytopenia. Maximum plasma levels of interleukin (IL)-10 and soluble tumor necrosis factor receptor-II correlated with the degree of thrombocytopenia, independently of viremia levels. Hepatic transaminase elevation correlated with plasma soluble IL-2 receptor levels and not with viremia levels. Quantitative differences in virus burden and host immune responses, and the timing of type 1 cytokine responses, have differing influences on the severity of disease manifestations during secondary dengue-3 virus infections.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=12001037&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttps://doi.org/10.1086/340365
dc.subjectImmunity
dc.subjectImmunology and Infectious Disease
dc.subjectImmunology of Infectious Disease
dc.subjectInfectious Disease
dc.titleDiffering influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections
dc.typeJournal Article
dc.source.journaltitleThe Journal of infectious diseases
dc.source.volume185
dc.source.issue9
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/infdis_pp/281
dc.identifier.contextkey10680677
html.description.abstract<p>Dengue hemorrhagic fever (DHF), the most severe form of illness following infection with a dengue virus, is characterized by plasma leakage, thrombocytopenia, and hepatic inflammation. The interrelationships among virus burden, immune activation, and development of DHF were examined in 54 children with secondary dengue-3 virus infections participating in a prospective, hospital-based study. DHF was associated with higher mean plasma viremia early in illness and earlier peak plasma interferon-gamma levels. Maximum plasma viremia levels correlated with the degree of plasma leakage and thrombocytopenia. Maximum plasma levels of interleukin (IL)-10 and soluble tumor necrosis factor receptor-II correlated with the degree of thrombocytopenia, independently of viremia levels. Hepatic transaminase elevation correlated with plasma soluble IL-2 receptor levels and not with viremia levels. Quantitative differences in virus burden and host immune responses, and the timing of type 1 cytokine responses, have differing influences on the severity of disease manifestations during secondary dengue-3 virus infections.</p>
dc.identifier.submissionpathinfdis_pp/281
dc.contributor.departmentDepartment of Medicine, Division of Infectious Diseases and Immunology
dc.contributor.departmentCenter for Infectious Disease and Vaccine Research
dc.source.pages1213-21


This item appears in the following Collection(s)

Show simple item record